Growth Metrics

Iridex (IRIX) Debt to Equity (2020 - 2021)

Iridex's quarterly Debt to Equity came in at $0.09 in Q2 2021, up 18.45% quarter-over-quarter from $0.07 in Q1 2021.

Iridex has reported Debt to Equity for 2 years, with the latest figure at $0.09 in Q2 2021.

  • For the quarter ending Q2 2021, Debt to Equity changed N/A year-over-year to $0.09; the trailing twelve-month figure through Apr 2021 stood at $0.09 (changed N/A YoY), and the FY2021 full-year result was $0.07, changed N/A from the prior year.
  • Debt to Equity for Q2 2021 stood at $0.09, up from $0.07 in the prior quarter.
  • The five-year high for Debt to Equity was $0.09 in Q3 2020, with the low at $0.07 in Q1 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 0.65
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 0.64
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 0.57
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 0.42
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 0.06
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 0.95
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 0.27
10 Iridex 18.87 Mn 14.27 Mn 4.74 Mn -

Historic Data

Download Data 🔒
DateValue
Apr 3, 2021 0.09
Jan 2, 2021 0.07
Sep 26, 2020 0.09